Aurobindo Pharma Ltd

NSE: AUROPHARMA · BSE: 524804 · Pharmaceuticals & Biotechnology · 63 announcements

Aurobindo Pharma Ltd news stories on ALFA NewsRead the news →

Share price: ₹1,682.00
Market cap: ₹97,691 Cr
Revenue (annual): ₹33,653 Cr
Net profit (annual): ₹3,505 Cr
P/E (TTM): 24.8×Sector 47.4×
Promoter holding: 51.88%+0.06% QoQ
FII holding: 16.38%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

21 May 2026 22:26 IST NSE

Aurobindo Pharma Board Meeting Outcome

Aurobindo Pharma appointed RPR & Associates and Ernst & Young LLP as secretarial and internal auditors. The board meeting also accepted MRR & Associates' resignation.

Execution: 60 months

Read the filing ↗

6 Apr 2026 08:24 IST BSE

Board Meeting Outcome

Aurobindo Pharma Board Meeting Outcome

Aurobindo Pharma's Board approved a ₹800 Crore share buyback at ₹1,475 per share via the tender offer route. The buyback represents 0.93% of paid-up equity capital. The record date is set for April 17, 2026, to determine eligibility for shareholders, including promoters.

Value: ₹800.0 Cr

Read the filing ↗